Important Information for GSK ADR Purchasers: Rosen Law Firm Announces Class Action Lawsuit and Lead Plaintiff Deadline
New York, NY – Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts (ADRs) of GSK plc (NYSE: GSK) between February 5, 2020, and August 14, 2022, both dates inclusive (the “Class Period”), of the important April 7, 2025, lead plaintiff deadline. The lawsuit alleges violations of the Securities Exchange Act of 1934 by GSK.
What is the Class Action Lawsuit About?
The complaint alleges that during the Class Period, GSK made false and/or misleading statements and/or failed to disclose that:
- GSK’s HIV drug, Sabril, had safety concerns;
- GSK had inadequate internal controls over financial reporting;
- GSK’s financial statements contained material misstatements and/or omissions;
- GSK had failed to disclose material information regarding its financial condition and business operations.
How Does This Impact Me as a GSK ADR Holder?
If you purchased GSK ADRs during the Class Period and suffered a loss as a result, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The lead plaintiff deadline is fast approaching, so it is important to act now. If you wish to serve as lead plaintiff, you must meet certain legal qualifications and be the first to file a lawsuit against the Company.
How Will This Impact the World?
The impact of this lawsuit on the world could be significant, as it may lead to increased transparency and accountability for pharmaceutical companies. The allegations against GSK regarding safety concerns with its HIV drug, Sabril, highlight the importance of thorough testing and transparency in the pharmaceutical industry. Additionally, the allegations regarding GSK’s financial reporting practices could lead to increased scrutiny and regulation of financial reporting processes.
Conclusion
Investors who purchased GSK ADRs during the Class Period may be entitled to compensation. The lead plaintiff deadline is fast approaching, so if you believe you may be eligible, it is important to act now. The lawsuit alleges that GSK made false and/or misleading statements and/or failed to disclose material information, which may have impacted your investment decisions. The potential impact of this lawsuit on the pharmaceutical industry and financial reporting practices could be significant.
If you have any questions or believe that you may be entitled to compensation, please contact Rosen Law Firm at 866-767-3653 or via email at [email protected] for more information.
